Cargando…

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms

Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics) of NENs. Their clinical success emerged receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fani, Melpomeni, Kolenc Peitl, Petra, Velikyan, Irina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374434/ https://www.ncbi.nlm.nih.gov/pubmed/28295000 http://dx.doi.org/10.3390/ph10010030

Ejemplares similares

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
por: Velikyan, Irina
Publicado: (2020)

Prospective of (68)Ga-Radiopharmaceutical Development
por: Velikyan, Irina
Publicado: (2013)

(68)Ga-Based Radiopharmaceuticals: Production and Application Relationship
por: Velikyan, Irina
Publicado: (2015)

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
por: Fani, Melpomeni, et al.
Publicado: (2022)

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses
por: Treglia, Giorgio, et al.
Publicado: (2021)

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
por: Barca, Cristina, et al.
Publicado: (2021)

EANM guideline on the validation of analytical methods for radiopharmaceuticals
por: Gillings, Nic, et al.
Publicado: (2020)

Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
por: Gillings, Nic, et al.
Publicado: (2021)

Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals
por: Koziorowski, J., et al.
Publicado: (2016)

Guidance on validation and qualification of processes and operations involving radiopharmaceuticals
por: Todde, S., et al.
Publicado: (2017)

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
por: Velikyan, Irina, et al.
Publicado: (2020)

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
por: Fersing, Cyril, et al.
Publicado: (2022)

Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management
por: Velikyan, Irina
Publicado: (2012)

PET Oncological Radiopharmaceuticals: Current Status and Perspectives
por: Lin, Mai, et al.
Publicado: (2022)

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
por: von Guggenberg, Elisabeth, et al.
Publicado: (2021)

Current status and future perspective of radiopharmaceuticals in China
por: Hu, Ji, et al.
Publicado: (2021)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Neuroendocrine tumor theranostics
por: Ichikawa, Yasushi, et al.
Publicado: (2022)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics via computational nuclear oncology
por: Rahmim, Arman, et al.
Publicado: (2022)

Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals
por: Carter, Korey P., et al.
Publicado: (2020)

Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents
por: Nurhidayah, Wiwit, et al.
Publicado: (2022)

Nutritional and vitamin status in patients with neuroendocrine neoplasms
por: Clement, Dominique SVM, et al.
Publicado: (2019)

Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms
por: Stankiewicz, Rafał, et al.
Publicado: (2022)

Current status of theranostics in prostate cancer
por: Virgolini, Irene, et al.
Publicado: (2017)

Neuroendocrine neoplasm: Current understanding
por: Lila, AR, et al.
Publicado: (2023)

Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines
por: Mohamed, Amr, et al.
Publicado: (2022)

Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives
por: Bai, Rilan, et al.
Publicado: (2022)

Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
por: Fani, Melpomeni, et al.
Publicado: (2020)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Models in Pancreatic Neuroendocrine Neoplasms: Current Perspectives and Future Directions
por: Forsythe, Steven D., et al.
Publicado: (2023)

EANM guideline on quality risk management for radiopharmaceuticals
por: Gillings, Nic, et al.
Publicado: (2022)

Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Alexandraki, Krystallenia I., et al.
Publicado: (2017)

The present status of radiopharmaceuticals in the country
por: Jalilian, Amir Reza, et al.
Publicado: (2016)

Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms
por: Canakis, Andrew, et al.
Publicado: (2022)

Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies
por: Paik, Woo Hyun, et al.
Publicado: (2022)

Current update on imaging for pancreatic neuroendocrine neoplasms
por: Segaran, Nicole, et al.
Publicado: (2021)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b2jvcqbfras3kvpcf1gf4s3uct